troglitazone has been researched along with Malignant Melanoma in 3 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Smith, AG | 1 |
| Beaumont, KA | 1 |
| Smit, DJ | 1 |
| Thurber, AE | 1 |
| Cook, AL | 1 |
| Boyle, GM | 1 |
| Parsons, PG | 1 |
| Sturm, RA | 1 |
| Muscat, GE | 1 |
| Paulitschke, V | 1 |
| Gruber, S | 1 |
| Hofstätter, E | 1 |
| Haudek-Prinz, V | 1 |
| Klepeisz, P | 1 |
| Schicher, N | 1 |
| Jonak, C | 1 |
| Petzelbauer, P | 1 |
| Pehamberger, H | 1 |
| Gerner, C | 1 |
| Kunstfeld, R | 1 |
| Mössner, R | 1 |
| Schulz, U | 1 |
| Krüger, U | 1 |
| Middel, P | 1 |
| Schinner, S | 1 |
| Füzesi, L | 1 |
| Neumann, C | 1 |
| Reich, K | 1 |
3 other studies available for troglitazone and Malignant Melanoma
| Article | Year |
|---|---|
PPARgamma agonists attenuate proliferation and modulate Wnt/beta-catenin signalling in melanoma cells.
Topics: Animals; Antineoplastic Agents; beta Catenin; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; C | 2009 |
Proteome analysis identified the PPARγ ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromans; Hu | 2012 |
Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; Chromans; Dose-Response Relationship, Drug; Fibrino | 2002 |